Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (20697)	7/31/2006 2:08:39 PM
From: Doc Bones	Respond to of 52153

I'm hoping for some American pie, so I added some RGEN at 3. No doubt RGEN is still speculative, but it's nicer to bet after the fact. Doc

To: Jibacoa who wrote (20697)	7/31/2006 6:05:21 PM
From: Biomaven	Read Replies (2) \| Respond to of 52153

<This isn't even the CTLA-4 patent suit I've been mostly talking about, so I can't claim credit for foreseeing this jump, but I'll take it anyway.> UPDATE 2-Court rejects ImClone argument in Repligen dispute Mon Jul 31, 2006 8:43am ET164 (Updates with share price reactions) BOSTON, July 31 (Reuters) - Repligen Corp. (RGEN.O: Quote, Profile, Research) shares leaped as much as 46 percent on Monday after it won a court ruling in a patent infringement suit against ImClone Systems Inc. (IMCL.O: Quote, Profile, Research). The ruling by the U.S. District Court for the District of Massachusetts eliminates a potential defense by ImClone in a suit over technology used to make ImClone's cancer drug Erbitux. ImClone's shares were down nearly 4 percent in midday trading. Repligen, a biopharmaceutical company based in Waltham, Massachusetts, said the court ruled in its and the Massachusetts Institute of Technology's favor. They claim ImClone infringed a patent covering certain genetic elements that increase protein production in a mammalian cell. Walter Herlihy, chief executive officer of Repligen, said a predecessor of Repligen's created a cell line under contract to the National Cancer Institute that was subsequently transferred to ImClone for use in research and development. Herlihy said the court found that these transfers did not exhaust the rights of either Repligen or MIT. MIT holds the patent for the technology, which it licensed exclusively to Repligen. Repligen and MIT plan to seek damages to compensate them for what they said is ImClone's unlicensed use of technology. ImClone, which had filed a motion for summary judgment in the case in an effort to dismiss all the claims by Repligen and MIT, said in a statement the case will now proceed to trial on the merits of its other defenses. ImClone said it will "vigorously defend" its claim that it does not infringe the patent. No trial date has yet been set. Repligen's shares rose 74 cents, or 31 percent, to $3.14 in midday trading on Nasdaq. Earlier they rose as high as $3.50. ImClone's shares fell $1.34, or 3.9 percent, to $32.58. © Reuters 2006. All Rights Reserved.